CA2366706A1 - Mammalian cytokines; related reagents and methods - Google Patents

Mammalian cytokines; related reagents and methods Download PDF

Info

Publication number
CA2366706A1
CA2366706A1 CA002366706A CA2366706A CA2366706A1 CA 2366706 A1 CA2366706 A1 CA 2366706A1 CA 002366706 A CA002366706 A CA 002366706A CA 2366706 A CA2366706 A CA 2366706A CA 2366706 A1 CA2366706 A1 CA 2366706A1
Authority
CA
Canada
Prior art keywords
polypeptide
amino acids
seq
mature
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002366706A
Other languages
English (en)
French (fr)
Inventor
Birgit Oppmann
Jacqueline C. Timans
Robert A. Kastelein
J. Fernando Bazan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2366706A1 publication Critical patent/CA2366706A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002366706A 1999-03-11 2000-03-09 Mammalian cytokines; related reagents and methods Abandoned CA2366706A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26790199A 1999-03-11 1999-03-11
US09/267,901 1999-03-11
PCT/US2000/006182 WO2000053631A1 (en) 1999-03-11 2000-03-09 Mammalian cytokines; related reagents and methods

Publications (1)

Publication Number Publication Date
CA2366706A1 true CA2366706A1 (en) 2000-09-14

Family

ID=23020618

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002366706A Abandoned CA2366706A1 (en) 1999-03-11 2000-03-09 Mammalian cytokines; related reagents and methods

Country Status (9)

Country Link
EP (2) EP1942114A3 (https=)
JP (1) JP2003500010A (https=)
AR (1) AR022890A1 (https=)
AT (1) ATE420894T1 (https=)
AU (1) AU3873200A (https=)
CA (1) CA2366706A1 (https=)
DE (1) DE60041393D1 (https=)
ES (1) ES2319958T3 (https=)
WO (1) WO2000053631A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804435A1 (fr) * 2000-01-27 2001-08-03 Pf Medicament COMPLEXE ISOLE COMPRENANT UNE PROTEINE NNT-1 ET EN OUTRE AU MOINS UNE PROTEINE CLF-1 ET/OU UNE PROTEINE sCNTFRalpha
US7045283B2 (en) * 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
EP1623011B1 (en) 2003-05-09 2013-01-02 Janssen Biotech, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
AU2006265002B2 (en) 2005-06-30 2012-09-20 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
EP3190125A1 (en) 2005-08-31 2017-07-12 Merck Sharp & Dohme Corp. Engineered anti-il-23 antibodies
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
AR065420A1 (es) 2007-02-23 2009-06-03 Schering Corp Anticuerpos anti-il-23 p19 de ingenieria
EP2426145B1 (en) 2007-02-23 2017-01-18 Merck Sharp & Dohme Corp. Engineered anti-il-23p19 antibodies
JP5337055B2 (ja) 2007-02-28 2013-11-06 メルク・シャープ・アンド・ドーム・コーポレーション 免疫性障害の処置のための組合せ治療
AU2008219684B2 (en) 2007-02-28 2014-04-17 Merck Sharp & Dohme Corp. Engineered anti-IL-23R antibodies
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
AU2018263868A1 (en) 2017-05-02 2019-12-12 Merck Sharp & Dohme Llc Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
KR102885113B1 (ko) 2018-10-18 2025-11-13 머크 샤프 앤드 돔 엘엘씨 항-rsv 항체의 제제 및 그의 사용 방법
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
CN113316458B (zh) 2018-11-07 2024-08-02 默沙东有限责任公司 抗lag3抗体和抗pd-1抗体的共制剂
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
WO2020234834A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
KR20230023663A (ko) 2020-05-21 2023-02-17 얀센 바이오테크 인코포레이티드 Il-23 및 tnf 알파에 대한 항체의 병용 요법으로 염증성 장질환을 치료하는 방법

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
DE3382317D1 (de) 1982-03-15 1991-07-25 Schering Corp Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5470952A (en) * 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5840530A (en) * 1995-08-01 1998-11-24 Hoffmann-La Roche Inc. DNA encoding receptors for the beta-2 chain of human IL-12
AUPO224696A0 (en) * 1996-09-11 1996-10-03 Amrad Operations Pty. Limited A novel haemopoietin receptor and genetic sequences encoding same
JP2001508309A (ja) * 1997-01-16 2001-06-26 ジェネティックス・インスチチュート・インコーポレーテッド ヘマトポイエチン受容体スーパーファミリーのメンバー
EP0977859B1 (en) * 1997-02-03 2004-08-11 Amgen Inc., The neurotrophic factor nnt-1
US5741772A (en) * 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
AU7276098A (en) * 1997-05-01 1998-11-24 Zymogenetics Inc. Mammalian cytokine-like receptor
JP2002507125A (ja) * 1997-06-30 2002-03-05 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド カルジオトロフィン様サイトカイン
GB9721961D0 (en) * 1997-10-16 1997-12-17 Glaxo Group Ltd Novel molecules
CA2311640A1 (en) * 1997-12-03 1999-06-10 Genentech, Inc. Polypeptides and nucleic acids encoding the same
WO1999035264A1 (en) * 1998-01-09 1999-07-15 Immunex Corporation H14 dna and polypeptides
AU2661199A (en) * 1998-02-06 1999-08-23 Schering Corporation Mammalian receptor proteins; related reagents and methods
SI1181366T2 (sl) * 1999-06-01 2013-10-30 Merck Sharp & Dohme Corp. Sesalski receptorski proteini; sorodni reagenti in postopki
FR2804435A1 (fr) * 2000-01-27 2001-08-03 Pf Medicament COMPLEXE ISOLE COMPRENANT UNE PROTEINE NNT-1 ET EN OUTRE AU MOINS UNE PROTEINE CLF-1 ET/OU UNE PROTEINE sCNTFRalpha

Also Published As

Publication number Publication date
EP1942114A3 (en) 2008-08-27
JP2003500010A (ja) 2003-01-07
ES2319958T3 (es) 2009-05-18
AR022890A1 (es) 2002-09-04
AU3873200A (en) 2000-09-28
DE60041393D1 (de) 2009-03-05
EP1942114A2 (en) 2008-07-09
WO2000053631A1 (en) 2000-09-14
ATE420894T1 (de) 2009-01-15
EP1159299B1 (en) 2009-01-14
EP1159299A1 (en) 2001-12-05

Similar Documents

Publication Publication Date Title
EP1002084B1 (en) Mammalian cytokine: interleukin-b30 and related reagents
US6479634B1 (en) IL-B30 proteins
EP1159299B1 (en) Mammalian cytokines; related reagents and methods
CA2343979C (en) Human interleukin-b50, therapeutic uses
US7390481B2 (en) Mammalian cytokine complexes
EP1200592B1 (en) Mammalian cytokines; related reagents
MXPA01009178A (en) Mammalian cytokines;related reagents and methods
HK1024932B (en) Mammalian cytokine: interleukin-b30 and related reagents
HK1131187A (en) Mammalian cytokine: interleukin-b30 and related reagents
HK1145336A (en) Mammalian cytokine: interleukin-b30 and related reagents
HK1113173A (en) Human interleukin-b50. therapeutic uses
HK1133023A (en) Methods of generating antibodies against cytokines

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued